McGlynn Margaret G's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 1, 2022
- Accession no.
- 0001209191-22-005895
- Filed
- Feb 1, 2022
- Trade date
- Jan 28, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.21M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McGlynn Margaret GCIK 0001215126 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 28, 2022 | Common Stock | MOption exerciseAcquired | +5,000 | $127.54 | +$637,700 | 6,099 | Direct | |
| Jan 28, 2022 | Common Stock | SSaleDisposed | −1,901 | $240.53F2,F3 | −$457,247.53 | 4,198 | Direct | |
| Jan 28, 2022 | Common Stock | SSaleDisposed | −800 | $241.83F3,F4 | −$193,464 | 3,398 | Direct | |
| Jan 28, 2022 | Common Stock | SSaleDisposed | −2,087 | $242.78F3,F5 | −$506,681.86 | 1,311 | Direct | |
| Jan 28, 2022 | Common Stock | SSaleDisposed | −212 | $243.24F3,F6 | −$51,566.88 | 1,099 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 28, 2022 | Common Stock | MOption exerciseDisposed | −5,000 | $127.54 | −$637,700 | 15,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Open market sales reported on this line occurred at a weighted average price of $240.53 (range $240.01 to $240.92).
Referenced by the price of 1 transaction in Table I.
- F3
Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 4 transactions in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $241.83 (range $241.16 to $242.15).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $242.78 (range $242.18 to $243.14).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $243.24 (range $243.21 to $243.27).
Referenced by the price of 1 transaction in Table I.
Remarks
Exhibit 24 - Power of Attorney